Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...
Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...
AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...
AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...
Studying the social behavior of animals in their natural environments is necessary for advancing our understanding of neurological processes. To achieve this, tracking multiple individuals ...
Tom's Guide on MSN12d
iOS 18.3 lets you identify plants and animals — here's how to do itVisual Intelligence on iPhone keeps getting better with each update. If you have an iPhone 16, iPhone 16 Pro, or iPhone 16 ...
A team of researchers has outlined a new approach for better understanding the depths of animal consciousness, a method that ...
Groundbreaking study shows machine learning can decode emotions in seven ungulate species. A game-changer for animal welfare? Can artificial intelligence help us understand what animals feel? A ...
CollPlant Biotechnologies , or 'CollPlant', a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue ...
AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback